Actinium Pharmaceuticals Announces That The First-Ever Preclinical Data From Its ATNM-400 Program In Non-Small Cell Lung Cancer Has Been Accepted For Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics Being Held October 22 – 26, 2025

Author: Benzinga Newsdesk | October 13, 2025 12:14pm

NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer (NSCLC) has been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22 – 26, 2025, at the Hynes Convention Center in Boston, Massachusetts. ATNM-400 is a highly innovative, first-in-class, Actinium-225 (Ac-225) antibody radioconjugate with preclinical data in both prostate cancer and NSCLC. Together, these two indications represent more than 500,000 new cases annually in the U.S. alone.

Posted In: ATNM